A small group of neurons modulates the amount of insulin that the pancreas must produce Blog Post

A research project co-chaired by Antonio Zorzano, at the Institute for Research in Biomedicine (IRB Barcelona) at PCB, and Marc Claret, at the August Pi i Sunyer Biomedical Research Institute – IDIBAPS, both members of the CIBERDEM network, emphasizes the importance of the neuronal mechanisms in the detection of nutrients and the control of glucose levels. The results published in Cell Metabolism help to understand diabetes in greater detail.

 

Launching of KeTLOD Project Knowledge Transfer in Organ Donation from Europe to China Blog Post

The University of Barcelona (UB) and the DTI Foundation, located at the Barcelona Science Park (PCB), are the main coordinators of the European project KeTLOD (Knowledge Transfer and Leadership in Organ Donation from Europe to China), an initiative of the European Union that aim to design the first postgraduate program in organ donation  in China and to implement it in seven universities all over the country. 

 

Tomàs Marquès-Bonet awarded by the Howard Hughes Medical Institute Blog Post

Researcher Tomàs Marquès-Bonet, director of the Institute for Evolutionary Biology (IBE), and leader of the Comparative Genomics group at CNAG-CRG at the Barcelona Science Park, has been awarded the International Early Career Award by the Howard Hughes Medical Institute (HHMI, USA). He will receive $ 650,000 spread over five years, starting in September 2017. A total of 1,600 researchers from around the world attended the call, of which only 41 were selected. To date, only 5 investigators in Spain have received this recognition.

 

Fresh financial and institutional support for the Research in Society programme Blog Post

Once again the ‘Research in Society’ programme run by the Barcelona Science Park (Parc Científic de Barcelona, PCB) will have the financial backing of the Spanish Foundation for Science and Technology (Fundación Española para la Ciencia y Tecnología) and Barcelona City Council in the shape of grants coming to €23,000 and €16,700 respectively. This funding from the two institutions will help secure the development of the PCB’s science popularisation activities and also recognises its firm commitment to driving measures that add to the social dimension of science.   

 

IBEC is bioprinting partner in major 3D printing hub in Catalonia Blog Post

The Institute for Bioengineering of Catalonia (IBEC), based at Barcelona Science Park, is to be part of a the Global 3D Printing Hub, a 3D printing infrastructure in Catalonia, which will receive up to 28 million euros from the Generalitat by 2020 to consolidate Catalonia as a world leader in 3D printing, one of the key technologies in industry 4.0. The Global 3D Printing Hub will be headquartered in 10.000m2 of the Campus Diagonal Besòs in Barcelona.

 

BIST awards the first five Ignite multidisciplinary projects Blog Post

In the framework of the BIST Founding Conference –held last Friday at the Center for Contemporary Culture of Barcelona– the Barcelona Institute of Science and Technology (BIST) –located at the Barcelona Science Park– announced the five winning proposals for the 1st BIST Ignite call. The program takes place in two phases: in the first, the selected projects will receive 20,000€ each. By the end of 2017, the two projects with the highest potential will be selected to receive additional funding of 50,000€.

 

Bionure project of the GAEM’s Accelerator Programme raises more than €1M via equity crowdfunding Blog Post

With more than €1M raised, Bionure’s campaign ‘#estamosaesto‘ (‘we are this close’) is currently overfunding on the Capital Cell crowdfunding platform.These funds will be used by the company to develop BN201, a promising first-in-class drug candidate halt the development of Multiple Sclerosis (MS). Bionure’s MS drug candidate is one of the projects promotes by the Accelerator Programme of GAEM Foundation from its headquarters at the Barcelona Science Park (PCB).

 

Minoryx successfully completes phase 1 clinical trial for lead candidate MIN-102 Blog Post

Minoryx Therapeutics – a drug development company specialized in the discovery and development of new drugs for orphan diseases, which has R& D laboratories at the Barcelona Science Park– announces that it has successfully completed its phase 1 trial with its lead compound MIN-102 targeting X-linked adrenoleukodystrophy (X-ALD), a life threatening orphan CNS disease with high unmet medical need.

 

The AECC supports cancer research at IRB Barcelona Blog Post

Today, Jelena Urosevic and Carles Barceló, postdoctoral fellows at the Institute for Research in Biomedicine (IRB Barcelona) at the Barcelona Science Park, will officially be presented with funding over 5 years from the Asociación Española Contra el Cáncer (AECC) for their respective research projects on colon cancer. To date, IRB Barcelona has secured AECC funding for eight cancer projects.